<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344018</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62092-22092</org_study_id>
    <secondary_id>EORTC-62092</secondary_id>
    <secondary_id>EORTC-22092</secondary_id>
    <secondary_id>EU-21113</secondary_id>
    <nct_id>NCT01344018</nct_id>
  </id_info>
  <brief_title>Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma</brief_title>
  <acronym>STRASS</acronym>
  <official_title>A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation
      therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that
      needs to be removed. It is not yet known whether surgery is more effective with or without
      radiation therapy in treating nonmetastatic retroperitoneal soft tissue sarcoma.

      PURPOSE: This randomized phase III trial is studying radiation therapy followed by surgery to
      see how well it works compared with surgery alone in treating patients with previously
      untreated nonmetastatic retroperitoneal soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess whether there is a difference in abdominal recurrence-free survival between
           retroperitoneal soft tissue sarcoma patients undergoing curative intent surgery alone
           and those undergoing preoperative radiotherapy followed by curative-intent surgery.

      Secondary

        -  To assess whether there is a difference in metastasis-free survival, abdominal
           recurrence-free interval, and overall survival between these patients.

        -  To assess tumor response in patients undergoing preoperative radiotherapy.

        -  To assess toxicity of preoperative radiotherapy given prior to curative-intent surgery
           in these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to institution and
      WHO performance status (0-1 vs 2). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo surgical resection of the tumor mass within 4 weeks following
           randomization.

        -  Arm II: Patients undergo 3-dimensional conformal radiation therapy (RT) or
           intensity-modulated RT within 8 weeks after randomization. RT continues 5 days a week
           for approximately 5.5 weeks. Patients undergo surgical resection of the tumor mass
           within 4-8 weeks after the completion of RT.

      Tumor tissue, normal abdominal wall fat, and peripheral blood may be collected during surgery
      to identify new prognostic factors for translational research.

      After completion of study therapy, patients are followed at day 60 post-surgery and every 6
      months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal recurrence-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity profile of preoperative radiotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response to preoperative radiotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to abdominal recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Surgery alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative radiotherapy followed by en-bloc surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Surgery alone</arm_group_label>
    <arm_group_label>Preoperative radiotherapy followed by en-bloc surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>Preoperative radiotherapy followed by en-bloc surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed retroperitoneal sarcoma (RPS) by local pathologist,
             imaging-guided or surgical biopsy, including the following:

               -  Primary soft tissue sarcoma of retroperitoneal space or infra-peritoneal spaces
                  of pelvis

               -  Sarcoma not originated from bone structure, abdominal, or gynecological viscera

               -  Unifocal tumor (not multifocal disease)

               -  Absence of extension through the sciatic notch or across the diaphragm

          -  The following histological sub-types are not allowed:

               -  Gastrointestinal stromal tumor (GIST)

               -  Rhabdomyosarcomas

               -  Primitive neuroectodermal tumor (PNET) or other small round blue cells sarcoma

               -  Osteosarcoma or chondrosarcoma

               -  Aggressive fibromatosis

               -  Sarcomatoid or metastatic carcinoma

          -  No metastatic disease

          -  Untreated disease

          -  Tumor must be operable and suitable for radiotherapy, based on the following criteria:

               -  Pre-treatment CT scan/MRI and multidisciplinary consultation with surgeon,
                  radiation oncologist, and radiologist (anticipated macroscopically complete
                  resection, R0/R1 resection)

                    -  No surgery anticipated to be R2 on the CT scan before randomization

               -  Must have American Society of Anesthesiologist (ASA) score ≤ 2

               -  None of the following unresectable criteria:

                    -  Involvement of superior mesenteric artery

                    -  Involvement of aorta

                    -  Involvement of bone

          -  Must have radiologically measurable disease (RECIST 1.1), as confirmed by
             abdomino-pelvic CT (with IV and PO contrast) or MRI (with IV contrast)

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  WBC ≥ 2,500/mm^3

          -  Platelet count ≥ 80,000/mm^3

          -  Total bilirubin &lt; 1.5 times the upper limit normal

          -  Calculated creatinine clearance normal

          -  Functional contra-lateral kidney to the side involved by the RPS as assessed by
             intravenous pyelogram

          -  Adequate cardiac function (NYHA class I-II)

          -  ECG normal (without clinically significant abnormalities)

          -  No history of any of the following disorders:

               -  Bowel obstruction

               -  Mesenteric ischemia

               -  Severe chronic inflammatory bowel disease

          -  Negative pregnancy test

          -  Not pregnant or nursing concurrently and for at least 1 month after the surgery

          -  Fertile patients must use effective contraception during the study treatment period
             and for at least 1 month after the surgery

          -  No co-existing malignancy within the past 5 years, except for adequately treated basal
             cell carcinoma of the skin or carcinoma in situ of the cervix

          -  No psychological, familial, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  No prior surgery (excluding diagnosis biopsy), radiotherapy, or systemic therapy

          -  No prior abdominal or pelvic irradiation for another prior malignancy or other disease

          -  No concurrent systemic anticancer treatment (chemotherapy, molecular-targeted therapy)

          -  No postoperative radiotherapy planned
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Bonvalot</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rick LM Haas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Kirkpatrick</last_name>
    <phone>+32 27741691</phone>
    <email>anne.kirkpatrick@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute &amp; Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Field</last_name>
      <email>julie_field@DFCI.Harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Sminkey</last_name>
      <email>gsminkey@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chandrajit P. Raut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet (101)</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Van Gestel</last_name>
      <phone>+32 25413242</phone>
      <email>dirk.vangestel@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Dirk Van Gestel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daphné Hompes</last_name>
      <phone>+ 32 16341826</phone>
      <email>daphne.hompes@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Erik Van Limbergen</last_name>
      <phone>+ 32 16346907</phone>
      <email>erik.vanlimbergen@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Daphne Hompes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Swallow</last_name>
      <phone>+ 1 416 586 1558</phone>
      <email>cswallow@mtsinai.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Charles Catton</last_name>
      <email>charles.catton@rmp.uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Swallow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame</name>
      <address>
        <city>Montreal QUEBEC</city>
        <state>Quebec</state>
        <zip>1560</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Wong</last_name>
      <email>philip.wong.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Philip Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Copenhagen</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Krarup-Hansen</last_name>
      <phone>+ 45 44535330</phone>
      <email>ankha@heh.regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Poul Geertsen</last_name>
      <phone>+ 45 44883083</phone>
      <email>poge@heh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Anders Krarup-Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eberhard Stoeckle</last_name>
      <email>e.stoeckle@bordeaux.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Guy Kantor</last_name>
      <phone>+ 33 556 333333</phone>
      <email>g.kantor@bordeaux.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eberhard Stoeckle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Meeus</last_name>
      <email>pierre.meeus@lyon.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Pierre Sunyach</last_name>
      <email>Marie-pierre.sunyach@lyon.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Meeus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Bonvalot, Dr</last_name>
      <phone>0033/142114383</phone>
      <email>sylvie.bonvalot@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile Le Pechoux</last_name>
      <email>cecile.lepechoux@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvie Bonvalot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Chemnitz</last_name>
      <phone>+ 49 22147897885</phone>
      <email>jens.chemnitz@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Moenig</last_name>
      <phone>+ 49 2214787440</phone>
      <email>stefan.moenig@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jens Chemnitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitaetsMedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hohenberger</last_name>
      <phone>+ 49 621 3832609</phone>
      <email>peter.hohenberger@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Frederik Wenz</last_name>
      <email>frederik.wenz@radonk.ma.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hohenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Belka</last_name>
      <phone>+ 49 8970954520</phone>
      <email>claus.belka@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Josephine Rauch</last_name>
      <phone>+ 49 8970953770</phone>
      <email>josephine.rauch@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claus Belka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Theisen</last_name>
      <phone>+ 49 8941405134</phone>
      <email>joerg.theisen@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Roeper</last_name>
      <email>barbara.roeper@lrz.tu-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joerg Theisen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico</name>
      <address>
        <city>Aviano Italy</city>
        <state>Aviano</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonino De Paoli</last_name>
      <phone>+39 0434659528</phone>
      <email>adepaoli@cro.it</email>
    </contact>
    <investigator>
      <last_name>Antonino De Paoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Quagliuolo</last_name>
      <phone>+ 39 0282244564</phone>
      <email>vittorio.quagliuolo@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Piera Navarria</last_name>
      <phone>+ 39 0282247459</phone>
      <email>Piera.navarria@cancercenter.humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Vittorio Quagliuolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gronchi</last_name>
      <phone>+ 390223903234</phone>
      <email>alessandro.gronchi@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Sangalli</last_name>
      <phone>+ 390223902480</phone>
      <email>claudia.sangalli@istitutotumori.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Grronchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Rastrelli</last_name>
      <phone>+ 39 0498215714</phone>
      <email>marco.rastrelli@ioveneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Scarzello</last_name>
      <email>g.scarzello@unipd.it</email>
    </contact_backup>
    <investigator>
      <last_name>Marco Rastrelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Haas</last_name>
      <phone>+ 31205122124</phone>
      <email>r.haas@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Fritz Van Coevorden</last_name>
      <phone>+ 31 205122552</phone>
      <email>coevor@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Rick Haas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. J. Van Ginkel</last_name>
      <phone>+ 31 503612317</phone>
      <email>r.j.van.ginkel@chir.umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>E. Pras</last_name>
      <phone>+ 31 503613674</phone>
      <email>e.pras@rt.umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>R. J. Van Ginkel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A D.G. Krol</last_name>
      <phone>+ 31 715263027</phone>
      <email>a.d.g.krol@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>H H Hartgrink</last_name>
      <phone>+ 31 715263610</phone>
      <email>h.h.hartgrink@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>A D.G. Krol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Bonenkamp</last_name>
      <phone>+ 31 243617365</phone>
      <email>han.bonenkamp@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>R. Snijers</last_name>
      <email>r.snijers@rther.umcn.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Han Bonenkamp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radium Hospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Stoldt</last_name>
      <phone>+ 47 22935742</phone>
      <email>stephan.stoldt@radiumhospitalet.no</email>
    </contact>
    <contact_backup>
      <last_name>Oyvind S. Bruland</last_name>
      <phone>+ 47 97174004</phone>
      <email>oyvind.bruland@medisin.uio.no</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Stoldt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center</name>
      <address>
        <city>Warsaw</city>
        <zip>02781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Szacht</last_name>
      <phone>+ 48 225463083</phone>
      <email>mszacht@coi.waw.pl</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Rutkowski</last_name>
      <phone>+ 48 225462184</phone>
    </contact_backup>
    <investigator>
      <last_name>Milena Szacht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramona Verges</last_name>
      <phone>+ 34 932746059</phone>
      <email>rverges60@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nivardo Rodriguez-Conde</last_name>
      <phone>+ 34 932746376</phone>
      <email>nirodriguez@vhebron.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ramona Verges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Corona</last_name>
      <phone>+34 91 330 30 00</phone>
      <email>coronaja@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Juan Antonio Corona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>60500</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Ahlen</last_name>
      <phone>+ 46 851772477</phone>
      <email>jan.ahlen@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Elisabet Lidbrink</last_name>
      <email>elisabet.lidbrink@karolinska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Ahlen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Medical Center</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Serriff</last_name>
      <phone>+ 44 1216272000</phone>
      <email>Jenny.sherriff@uhb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>D. Gousevitch</last_name>
      <email>d.gousevitch@uhb.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Sherriff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Wilson</last_name>
      <phone>+ 44 1173422409</phone>
      <email>Paula.wilson@UHBristol.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tim Wittlestone</last_name>
      <phone>+ 44 1173422795</phone>
      <email>tim.wittlestone@uhbristol.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Western Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Fragkandrea-Nixon</last_name>
      <phone>+ 44 13133607</phone>
      <email>joanna.nixon@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Malcolm Dunlop</last_name>
      <email>malcolm.dunlop@nhlothian.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Fragkandrea-Nixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson-Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Cowie</last_name>
      <phone>+ 44 14113017053</phone>
      <email>fiona.cowie@ggc.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Chong</last_name>
      <email>peter.chong@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>fiona Cowie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust - St. James'S University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Turner</last_name>
      <phone>+ 44 1132067677</phone>
      <email>rob.turner@leedsth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kieran Horgan</last_name>
      <phone>+ 44 1132433144</phone>
      <email>kieran.horgan@leedsth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Rob Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Seddon</last_name>
      <phone>+ 44 2073809866</phone>
      <email>beatrice.seddon@uclh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Arjun Shankar</last_name>
      <email>arjun.shankar@uclh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Beatrice seddon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Strauss</last_name>
      <phone>+ 44 2078818081</phone>
      <email>dirk.strauss@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Aisha Miah</last_name>
      <phone>+ 44 2078082363</phone>
      <email>aishamiah@doctors.org.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Wylie</last_name>
      <phone>+ 44 1614463341</phone>
      <email>James.wylie@christie.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Noel W. Clarke</last_name>
      <phone>+ 44 16114463364</phone>
      <email>noel.clarke@christie.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>James Wylie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Lee</last_name>
      <phone>+ 44 1912138462</phone>
      <email>daniela.lee@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Derek Manas</last_name>
      <email>derek.manas@nuth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital campus</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Esler</last_name>
      <email>claire.esler@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Simon Parsons</last_name>
      <phone>+ 44 01159691169</phone>
      <email>simon.parsons@nuh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Claire Esler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Robinson</last_name>
      <phone>+ 44 1142265221</phone>
      <email>m.h.robinson@sheffield.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lynda Wyld</last_name>
      <phone>+ 44 1142268640</phone>
      <email>l.wyld@sheffield.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant mesenchymoma</keyword>
  <keyword>stage I adult soft tissue sarcoma</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

